← Patent-cliff monitor small molecule WAYRILZ RILZABRUTINIB
Loss of exclusivity February 2041 latest FDA-listed patent expiry
Company Genzyme → See this company's full patent-cliff portfolio Drug detail Brand name WAYRILZ Active ingredient RILZABRUTINIB Strength 400MG Dosage form TABLET Route ORAL Modality Small molecule FDA approval August 2025 Marketing status RX
Listed patents Patent Expires Type 11708370 February 2041 substance 12178818 October 2040 use U-4267 9994576 September 2033 substance, product 9266895 September 2033 substance, product 8940744 September 2033 substance, product 9580427 March 2033 substance, product
Regulatory exclusivity Code Expires ODE-552 August 2032 NCE August 2030
Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.